Board of Directors
Omid Farokhzad
Chair & Chief Executive Officer
Omid Farokhzad
Chair & Chief Executive Officer
Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
Meeta Gulyani
Member of Novo Advisory Group
Meeta Gulyani
Member of Novo Advisory Group
Meeta Gulyani has been a member of Novo Advisory Group since October 2023. She was formerly Head of Strategy, Business Development, and Transformation for Merck KGaA’s Life Science business, where she led the development of sector strategy and strategic planning across the organization. Prior to that, Meeta served as Executive Vice President and Head of Strategy and Global Franchises for Merck’s Biopharma business where she oversaw global business franchises, including Oncology, Neurology, Fertility, and General Medicine. Prior to joining Merck, Meeta served as General Manager for South Asia at Roche and held leadership positions in global portfolio management at Roche and marketing at Sanofi-Aventis. She also worked as a strategy consultant with Monitor Consulting Group. Meeta holds an MBA from the Asian Institute of Management, Philippines, and a bachelor’s degree in economics from Delhi University.
David Hallal
Former Chief Executive Officer at Alexion Pharmaceuticals
David Hallal
Former Chief Executive Officer at Alexion Pharmaceuticals
David Hallal is CEO, Chairman and Co-Founder at ElevateBio, as well as CEO and Chairman at AlloVir, and ElevateBio company. He is also Chairman of the Board of Directors at the biotechnology companies iTeos Therapeutics and Scholar Rock. Prior to his roles at iTeos and Scholar Rock, David was Chief Executive Officer of Alexion Pharmaceuticals, which he first joined in 2006. In addition to his CEO role, David also served as Board member, Chief Operating Officer, Chief Commercial Officer and Head of Commercial Operations. Before joining Alexion, David served as Vice President of Sales for OSI Eyetech from 2004 to 2006. He served as Head of Sales at Biogen from 2002 to 2004, and before that, he was at a variety of leadership roles at Amgen from 1992 to 2002. David began his pharmaceutical career at The Upjohn Company, where he was a sales representative from 1998 to 1992. He has a B.A. in psychology from the University of New Hampshire.
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Dr. Langer is the Chair of Seer’s Scientific Advisory Board. He is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Terry McGuire
Founding Partner of Polaris Partners
Terry McGuire
Founding Partner of Polaris Partners
Terry McGuire is Founding Partner of Polaris Partners. As a venture capitalist, he has invested in more than 50 companies, and has also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkemes) and MicroCHIPS (private). Companies that Terry has supported have raised over $6 billion in equity and corporate capital. In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors, and in 2011, he was listed in Forbes’ Midas 100 List of Top Tech Investors. He currently chairs the Board of the Thayer School for Engineering, Dartmouth College, and serves on the Boards of the David Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS). Terry has a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.
Deep Nishar
Partner at General Catalyst
Deep Nishar
Partner at General Catalyst
Deep Nishar is a Partner at General Catalyst. Prior to joining General Catalyst, Deep led Softbank’s investments in frontier tech, life sciences and enterprise software. Deep has more than 20 years of experience in helping build and grow software and internet businesses. Prior to joining SoftBank, Deep served as Senior Vice President of Products and User Experience at LinkedIn. He also held senior executive roles at Google, and was previously the Founder of enterprise software company Patkai Networks. He currently sits on the board of directors of 8 companies, including Relay Therapeutics, Inc. and Vir Bio, Inc.. Deep holds an MBA from Harvard Business School where he graduated as a Baker Scholar; an MSEE from the University of Illinois at Urbana-Champaign; and a Bachelor of Technology with honors from the Indian Institutes of Technology, Kharagpur. Deep has co-authored 14 patents, and is a recipient of the Google Founders Award which is given to employees who made extraordinary contributions to the company.
Nicolas Roelofs
Former President, Life Sciences Group, Agilent Technologies
Nicolas Roelofs
Former President, Life Sciences Group, Agilent Technologies
Nicolas Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Laboratories, Inc., and Chief Operating Officer at Stratagene Inc. He has previously served on the boards of several public and private companies including Olink Holding AB. Nick currently serves as chairman of Sengenics Corporation LLC, a board member of Velsera, LGC Group, and an advisory board member of 908 Devices Inc. Nick holds a doctorate in organic chemistry from University of Nevada, Reno, a master’s degree in organic chemistry from Iowa State University, and a bachelor’s degree in chemistry, biology, and German from Simpson College.
Clinical & Scientific Advisors
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Robert Langer, Sc.D.
Co-Chairman of Scientific Advisory Board
Dr. Langer is the Chair of Seer’s Scientific Advisory Board. He is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Steven Carr, Ph.D.
Senior Director of Proteomics at the Broad Institute of MIT and Harvard
Steven Carr, Ph.D.
Senior Director of Proteomics at the Broad Institute of MIT and Harvard
Dr. Carr is senior director of proteomics at the Broad Institute of MIT and Harvard, and an institute scientist. He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine. His research has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response. Prior to returning to academia in 2004, Dr. Carr held scientific leadership positions at GlaxoSmithKline where he was the director of computational and structural sciences and at Millennium Pharmaceuticals where he was senior director of protein science and technology. He has more than 400 publications, and he is deputy editor of Molecular and Cellular Proteomics, the leading journal in the field of proteomics. Dr. Carr received his B.S. from Union College and Ph.D. from MIT.
Vivek Farias, Ph.D.
Chair of Data Committee
Vivek Farias, Ph.D.
Chair of Data Committee
Dr. Farias is the Chair of the Data Committee of Seer’s Scientific Advisory Board. He is the Patrick J. McGovern (1959) Professor at the MIT Sloan School, affiliated with the Operations Management and Operations Research Center at MIT. His research focuses on optimization and inference from large-scale stochastic systems (ranging from supply chains to protein networks). He serves on the editorial boards of the journals Operations Research, Management Science and the Informs Journal on Optimization. He is also Chief Technology Officer of Celect, a company focused on advanced analytics solutions for supply chains. Dr. Farias received his B.S. in Computer Engineering from the University of Arizona, and his Ph.D. in Electrical Engineering from Stanford University.
Charles Cantor, Ph.D.
Emeritus Professor at Boston University
Charles Cantor, Ph.D.
Emeritus Professor at Boston University
Dr. Cantor is Professor Emeritus of Biomedical Engineering at Boston University. He is also the former Chief Scientific Officer of Sequenom, Inc., a San Diego genetics testing company, and now part of Lab Corp. His research has focused on identifying biological problems that are resistant to conventional analytical approaches and then developing new methodologies or techniques for solving these problems. His laboratory has developed methods for separating large DNA molecules, for studying structural relationships in complex assemblies of proteins and nucleic acids, and for sensitive detection of proteins and nucleic acids in a variety of settings. He is a member of the U.S. National Academy of Science. Dr. Cantor has published more than 400 peer reviewed articles, been granted 54 patents, and co-authored a three-volume textbook on Biophysical Chemistry. He received his A.B. in Chemistry from Columbia University, and his Ph.D. in Biophysical Chemistry from University of California, Berkeley.
Jennifer Van Eyk, Ph.D.
Erika Glazer Chair in Women's Heart Health, Director of Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, Director of Basic Science Research in the Women's Heart Center, Professor in Medicine and in Biomedical Sciences at Ce
Jennifer Van Eyk, Ph.D.
Erika Glazer Chair in Women's Heart Health, Director of Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, Director of Basic Science Research in the Women's Heart Center, Professor in Medicine and in Biomedical Sciences at Ce
Jennifer Van Eyk, Ph.D. is an international leader in the area of clinical proteomics and her lab has focused on developing technical pipelines for de novo discovery and larger scale quantitative mass spectrometry methods. This includes multiple reaction monitoring (MRM, also known as SRM) and most recently data independent acquisition. Dr. Van Eyk's laboratory is well known for the extreme technical quality of the data generated, rigorous quality control with tight %CV while applying these to key clinical questions. The aim is to maximize throughput and reproducibility in order to move targeted and robust discovery methods into large population healthy continuous assessment and clinical grade assays focusing on brain and cardiovascular diseases.
Josh Coon, Ph.D.
Chair of Proteomics Committee
Josh Coon, Ph.D.
Chair of Proteomics Committee
Dr. Josh Coon is the Chair of the Proteomics Committee of Seer’s Scientific Advisory Board. Dr. Coon is a chemist and professor of Chemistry and Biomolecular Chemistry at the University of Wisconsin-Madison. He received his graduate degree in Chemistry from the University of Florida and later worked at the laboratory of Professor Don Hunt in Charlottesville, Virginia, where he co-developed the widely used electron transfer dissociation (ETD) method for peptide sequencing. Dr. Coon is the Thomas and Margaret Pyle Chair at the Morgridge Institute for Research and has published over 300 peer-reviewed manuscripts, received numerous awards including the Biemann Medal from the American Society for Mass Spectrometry, the Pittsburgh Conference Achievement Award from the Pittcon Society, and most recently the ACS Chemical Instrumentation Award. Dr. Coon invented the widely practiced method of parallel reaction monitoring, many technologies related to multi-omic analysis, and is a leader in the field of mass spectrometry-based proteomics. Dr. Coon's laboratory group has produced over 40 PhD graduates and 15 postdoctoral scholars.
Luis Diaz, M.D.
Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering
Luis Diaz, M.D.
Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering
Dr. Diaz is the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center. He was previously a faculty member and physician at the Johns Hopkins University School of Medicine, where he was a member of the renowned Ludwig Center for Cancer Genetics and Therapeutics and was Director of the Swim Across America Laboratory. Dr. Diaz founded several cancer genomics entities including Inostics, PapGene and Personal Genome Diagnostics, Inc. His research has focused on cancer mutations as biomarkers in circulating tumor DNA for cancer screening and monitoring. Dr. Diaz has received numerous awards, including the 2013, 2014 and 2017 AACR Team Science Award, and the Waun Ki Hong Award for Outstanding Acheivement in Cancer Research. He received his B.S. in microbiology, his M.D. from the University of Michigan, his internal medicine residency training at the Osler Medical Service, and his medical oncology fellowship training at Johns Hopkins University School of Medicine. Dr. Diaz currently leads the SU2C Colon Cancer Dream Team, is Editor-in-Chief of Cancer Discovery and is an elected member of the American Society of Clinical Investigation (ASCI).
Chris Mason, Ph.D.
Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine; Director of the WorldQuant Initiative for Quantitative Prediction
Chris Mason, Ph.D.
Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine; Director of the WorldQuant Initiative for Quantitative Prediction
Dr. Chris Mason is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and Director of the WorldQuant Initiative for Quantitative Prediction. His laboratory creates and deploys new genomics technologies and predictive algorithms for medicine, which helps to ameliorate human disease and lays the foundation for long-term human survival on other planets. Dr. Mason’s work spans >300 peer-reviewed papers, five patents, five diagnostics tests, and the foundation of 10 biotechnology companies and 3 non-profits. Dr. Mason also holds affiliate faculty appointments at the New York Genome Center, Yale Law School, and the Consortium for Space Genetics at Harvard Medical School. He is the author of The Next 500 Years: Engineering Life to Reach New Worlds.
Mark McClellan, Ph.D., M.D.
Founding Director of the Duke-Margolis Center for Health Policy
Mark McClellan, Ph.D., M.D.
Founding Director of the Duke-Margolis Center for Health Policy
Dr. McClellan is the Director and Robert J. Margolis MD, Professor of Business, Medicine and Health Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University. Previously, he was Senior Fellow in Economic Studies at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of U.S. Food and Drug Administration (FDA). He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. Dr. McClellan holds multiple additional roles including: founding chair and current board member, Reagan-Udall Foundation for the FDA; member, National Academy of Medicine; co-chair, guiding committee of the Health Care Payment Learning and Action Network; research associate, National Bureau of Economic Research; and Senior Faculty Advisor, University of Texas Dell Medical School. Dr. McClellan also serves on the boards of Johnson & Johnson, Cigna and Alignment Healthcare.
Bruce Wilcox, Ph.D.
Chief Technology Officer at PrognomiQ
Bruce Wilcox, Ph.D.
Chief Technology Officer at PrognomiQ
Governance
The Board of Directors of Seer, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.